As immunotherapy for cancer continues to evolve—so has the Association of Community Cancer Centers—adapting to meet the changing needs of the oncology community.
The ACCC Immuno-Oncology Institute is the only initiative dedicated to educating multidisciplinary teams to go beyond a clinical understanding of IO and tackle real-world implementation issues. With the care of patients on immunotherapies now extending beyond the cancer team, the ACCC Immuno-Oncology Institute is at the forefront of developing critical education to empower healthcare professionals across care delivery settings.
Under the guidance of the IO Institute Executive Committee, multispecialty Working Groups were established to focus on Big Data, Telemedicine, Care Coordination and Communication, and Training and Education. IO Working Groups members share their expertise, knowledge, and forward-looking perspectives to provide a framework for developing proactive strategies for effective delivery of these new and emerging therapies.
For more information on this project, please contact the ACCC Provider Education department.
Best Practices for Implementing Cancer Immunotherapy in the Community
CAR-T Cell Therapies in Community Oncology
The Evolving Immunotherapeutic Landscape in Renal Cell Carcinoma
Managing Immune-Related Adverse Events
Optimizing Outcomes for Patients with Urothelial Carcinoma
Overcoming Obstacles in Integrating Immunotherapies for Cancer in the Community Setting
Preparing Community Providers for Bispecific Antibodies
Preparing for New Cellular Therapies: Tumor-Infiltrating Lymphocytes
Survivorship in the Era of IO
Dr. Sanjay Juneja explores how—with many cancers now being treated like a chronic disease—it may be time to cancel the term “a cure for cancer.”
In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond.
Learn about dermatology’s role in the cancer care continuum and how cancer teams can better integrate dermatology into the immunotherapy care process.
We explore how immunotherapy clinical trials have been affected by the pandemic and what cancer programs can do to safely and effectively administer clinical trials.
Learn about the mental health implications of treatment with cancer immunotherapy, and how cancer care providers can better integrate mental health awareness into the IO care continuum.
We sat down with journalist Mary Elizabeth Williams, one of the first patients treated with combination immunotherapy, to discuss her experience as an IO patient and how to bridge communication gaps among patients, doctors, and researchers.
Learn why a trip to the emergency department is different for patients who receive immunotherapy for cancer, what information helps ED clinicians, and what busy emergency department providers need to know about immune-related adverse events.
Learn about the transition from immunotherapy into post-treatment survivorship, how it differs from chemotherapy, and why coordination and communication among providers, patients, and caregivers is essential.
ACCC Releases Annual Report on Current State of Immuno-Oncology
The ASCO Post, Sep 10, 2021
Community Oncology Professionals Highlight Need for More Education on Immunotherapies
Targeted Oncology, Aug 11, 2021
ACCC Survey Reveals Biggest Challenges and Concerns Regarding IO Therapies
AJMC, Aug 4, 2021
ACCC Report: Immunotherapy Research Grew in 2020 Despite COVID-19 Pandemic
OncLive, Aug 7, 2021
ACCC Immuno-Oncology Institute Releases Report on the State of Immuno-Oncology
Where Does Survivorship Stand in the Era of Immuno-Oncology?
Oncology Times, Jan 5, 2020
Improving Immunotherapy Implementation in Community Practice
Oncology Nursing News, June 17, 2019
An Evidence-Based Argument Is Often the Fastest Route to Immunotherapy Authorization
OncLive, April 30, 2019
Telemedicine working group aims to address ‘big gaps’ of emergency cancer care
HemOnc Today, April 25, 2019
Download IO Wallet Card
Download Article & Companion Guide
See All Immuno-Oncology Insights